Leerink Partnrs Issues Optimistic Estimate for AURA Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – Equities researchers at Leerink Partnrs raised their FY2024 EPS estimates for shares of Aura Biosciences in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($1.67) per share for the year, up from their prior forecast of ($1.68). The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.44) EPS, FY2025 earnings at ($1.93) EPS and FY2026 earnings at ($2.21) EPS.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02.

Other analysts also recently issued reports about the company. Scotiabank increased their target price on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. BTIG Research upped their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Finally, JMP Securities upped their target price on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, September 13th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Trading Down 3.5 %

NASDAQ AURA opened at $9.97 on Friday. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38. The stock’s fifty day moving average price is $9.75 and its 200-day moving average price is $8.50. The stock has a market cap of $494.61 million, a P/E ratio of -5.81 and a beta of 0.33.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the transaction, the chief technology officer now owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This represents a 5.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $12.04, for a total transaction of $300,903.68. Following the completion of the transaction, the insider now owns 329,847 shares in the company, valued at approximately $3,971,357.88. The trade was a 7.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,259 shares of company stock worth $780,699 over the last quarter. Insiders own 5.40% of the company’s stock.

Institutional Trading of Aura Biosciences

Large investors have recently modified their holdings of the company. Long Focus Capital Management LLC increased its stake in shares of Aura Biosciences by 113.4% during the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after buying an additional 561,766 shares during the period. Levin Capital Strategies L.P. grew its holdings in Aura Biosciences by 194.5% during the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after acquiring an additional 216,266 shares in the last quarter. Bank of New York Mellon Corp increased its position in Aura Biosciences by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock valued at $1,081,000 after purchasing an additional 48,549 shares during the period. Dimensional Fund Advisors LP increased its position in Aura Biosciences by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock valued at $1,892,000 after purchasing an additional 41,711 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Aura Biosciences in the 3rd quarter valued at about $169,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.